Here are the 10-Q quarterly reports from Pediatrix Medical Group, Inc. (MD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MD filings page.
Pediatrix Medical Group, Inc. (MD) reported third-quarter 2026 net revenue of $501.4 million, up from $492.9 million a year earlier, while net income was $47.0 million versus $71.7 million. Operating income was $65.2 million versus $68.1 million; Adjusted EBITDA was $85.5 million versus $87.3 million, while Adjusted EPS was $0.72 versus $0.67. For the first nine months, revenue was $1.465 billion versus $1.420 billion, net income was $116.4 million versus $131.7 million, and Adjusted EBITDA was $220.1 million versus $209.7 million.
Net cash from continuing operating activities for the nine months was $114.5 million, compared with $160.1 million a year earlier; Pediatrix cited working-capital use, including incentive compensation payments, and lower cash collections. It repurchased 3,119,735 shares in the quarter at an average $26.60 per share; $21.5 million remained under its August 2025 program as of September 30, 2026. Cash and equivalents were $311.9 million, with $450.0 million available on its revolving credit line as of September 30, 2026. The Term A Loan's final payment of $171.9 million is due at maturity in February 2027. Pediatrix also completed a maternal-fetal medicine practice acquisition for $7.9 million, including $7.0 million paid at closing.
Pediatrix Medical Group delivered modest growth for the quarter and six months ended June 30, 2026. Net revenue reached $487.8 million in Q2 and $964.0 million year‑to‑date, both up 4.0% from 2025, driven by acquisitions and same‑unit reimbursement gains, partly offset by lower patient volumes, especially in neonatology.
Q2 income from operations slipped to $56.9 million with an 11.7% operating margin versus 12.8% a year earlier, as practice salaries and benefits and transformational and restructuring costs increased. However, six‑month net income improved to $69.4 million and diluted EPS to $0.85, with Adjusted EBITDA rising to $134.6 million and Adjusted EPS to $1.07.
Cash and cash equivalents fell to $288.9 million, and operating cash flow from continuing operations turned to a $3.2 million use of cash, mainly from incentive compensation and working capital. The company spent $61.7 million repurchasing 2.8 million shares, while maintaining leverage with a $184.4 million Term A Loan, $400.0 million of 2030 Notes and an undrawn $450.0 million revolver. Days sales outstanding improved to 42.5 days, and management expects existing cash, cash generation and credit capacity to cover needs for at least the next 12 months.
Pediatrix Medical Group reported stronger quarterly results. Net revenue for the three months ended March 31, 2026 rose to $476.2 million from $458.4 million, driven mainly by a 2.8% increase in same-unit revenue and contributions from recent acquisitions.
Net income increased to $29.6 million from $20.7 million, with diluted EPS up to $0.36 from $0.24 and operating margin improving to 8.7% from 7.0%. Adjusted EBITDA grew to $58.2 million from $49.2 million. The company ended the quarter with $205.8 million in cash, no borrowings on its $450.0 million revolver, and completed a $7.9 million maternal-fetal medicine acquisition while repurchasing about 1.0 million shares for $19.9 million.
Pediatrix Medical Group (MD) reported stronger Q3 results. Net revenue was $492.9 million versus $511.2 million a year ago, reflecting practice dispositions partly offset by growth at ongoing sites. Net income rose to $71.7 million from $19.4 million, and diluted EPS increased to $0.84 from $0.23. Adjusted EBITDA improved to $87.3 million from $60.2 million as operating margin expanded to 13.8%.
Same‑unit net revenue increased 8.0%, driven by better collections, higher patient acuity in neonatology, higher hospital administrative fees, and a slightly favorable payor mix. Transformational and restructuring expenses declined to $6.0 million. Non‑operating results benefited from a $20.9 million net gain on investments in divested businesses.
For the nine months, revenue was $1.42 billion and net income was $131.7 million. Cash and cash equivalents rose to $340.1 million, aided by lower days sales outstanding of 43.1 days. The company acquired women’s and children’s practices for $19.2 million and repurchased 1.2 million shares for $20.9 million under a new $250 million authorization. Debt included $400.0 million of 2030 notes and $201.6 million on the Term A Loan with $450.0 million revolver availability.